Novartis AG
DOSING SCHEDULE OF A WNT INHIBITOR AND AN ANTI-PD-1 ANTIBODY MOLECULE IN COMBINATION

Abstract:

The present disclosure relates to the field of pharmacy, particularly to a Wt inhibitor and a PD-1 inhibitor for use in the treatment of cancer. Specifically, the disclosure relates to a pharmaceutical combination comprising a Wnt inhibitor, or a pharmaceutically acceptable salt thereof, and a PD-1 inhibitor, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, to a method for the treatment of cancer that involves administering the combination and to the use of the combination for the manufacture of a medicament for the treatment of cancer.